A Phase 3 interventional study of ruxolitinib and Vehicle in Vitiligo, sponsored by Incyte Corporation. Completed at 84 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.
Among the 14 studies testing ruxolitinib in Vitiligo, this one has the largest enrollment, is the only one that started in 2020, is one of 6 in phase 3, and was the 5th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in Argentina, Austria, Belgium and 11 more countries
Ages 6–11
Incyte Corporation · Sites in United States, Canada
Ages 2–11
Hospital Authority, Hong Kong · Sites in Hong Kong
Ages 18–85
Kafrelsheikh University · Sites in Egypt
Ages 12+
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 2–11
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2016; this study’s year is marked. 1 started in 2020.
This study's enrollment of 458 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 90 across the 14 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 6 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
12 studies in Vitiligo by Incyte Corporation: 2 open now, 4 under way, 4 of them phase 3. Of 8 finished, 8 (100%) have results posted.
Among the 12 studies in Vitiligo by Incyte Corporation, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 7 in phase 3, and was the 4th registered.
Incyte Corporation’s Vitiligo studies by the year they started, since 2017.
2 of the studies testing ruxolitinib in Vitiligo that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06804811Phase 3Incyte CorporationA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | 2027-04-30 |
| NCT07909668Kafrelsheikh UniversityTopical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ruxolitinib in Vitiligo, from their registry updates:
Among Incyte Corporation’s 12 in Vitiligo:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed either Study NCT04052425 or NCT04057573 (parent studies) in which the participants will have been using ruxolitinib cream BID for the previous 28 to 52 weeks depending on their initial randomization in the parent study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream.
Drug: ruxolitinib
Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream.
Drug: Vehicle
Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.
Drug: ruxolitinib
ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
Also known as: INCB018424 Cream
Vehicle cream is a topical formulation applied as a thin film to affected areas.
Time to Relapse (Defined as <F-VASI75)
Relapse was defined as a loss of 75% improvement from Baseline in the Face Vitiligo Area Scoring Index score (F-VASI75) response, assessed as percentage improvement in the F-VASI score at Baseline (Day 1 of the parent study) to \<75%.
Time frame: from Week 52 (first visit of this Treatment Extension study) to Week 104 (end of treatment in this Treatment Extension study)
Time to Loss of Adequate Response
Loss of adequate response was defined as a loss of 90% improvement from Baseline in the F-VASI score (F-VASI90) response, assessed as percentage improvement in the F-VASI score at Baseline (Day 1 of the parent study) to \<90%.
Time frame: from Week 52 (first visit of this Treatment Extension study) to Week 104 (end of treatment in this Treatment Extension study)
Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score During the Extension Treatment Period
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Percentage of Participants Achieving a ≥75% Improvement From Baseline in the F-VASI (F-VASI75) Score During the Extension Treatment Period
An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Percentage of Participants Achieving a ≥90% Improvement From Baseline in the F-VASI (F-VASI90) Score During the Extension Treatment Period
An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Mean F-VASI Scores During the Extension Treatment Period
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Change From Baseline in F-VASI Scores During the Extension Treatment Period
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Percent Change From Baseline in F-VASI Scores During the Extension Treatment Period
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline (BL); up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score During the Extension Treatment Period
A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Percentage of Participants Achieving a ≥75% Improvement From Baseline in the T-VASI (T-VASI75) Score During the Extension Treatment Period
A T-VASI75 responder achieved at least 75% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Percentage of Participants Achieving a ≥90% Improvement From Baseline in the T-VASI (T-VASI90) Score During the Extension Treatment Period
A T-VASI90 responder achieved at least 90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Mean T-VASI Scores During the Extension Treatment Period
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Change From Baseline in T-VASI Scores During the Extension Treatment Period
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline=post-Baseline value minus the Baseline value.
Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Percent Change From Baseline in T-VASI Scores During the Extension Treatment Period
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Mean Facial Body Surface Area (F-BSA) During the Extension Treatment Period
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Data are presented as the percentage of BSA involvement in the face as compared to total BSA.
Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Change From Baseline in F-BSA During the Extension Treatment Period
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented as the percentage of BSA involvement in the face as compared to total BSA.
Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Percent Change From Baseline in F-BSA During the Extension Treatment Period
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Mean Total Body Surface Area (T-BSA) During the Extension Treatment Period
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Data are presented as the percentage of BSA involvement in the total body.
Time frame: up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Change From Baseline in T-BSA During the Extension Treatment Period
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented as the percentage of BSA involvement in the total body.
Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Percent Change From Baseline in T-BSA During the Extension Treatment Period
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) Score of 4 or 5 During the Extension Treatment Period
The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.
Time frame: Baseline; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Change From Week 52 in Dermatology Life Quality Index (DLQI) Total Score During the Extension Treatment Period
The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Participants age ≥16 years answered the questionnaire with: (1) very much; (2) a lot; (3) a little; or (4) not at all. The questionnaire was analyzed under 6 headings: Symptoms and feelings (Questions 1 and 2); Daily activities (Questions 3 and 4); Leisure (Questions 5 and 6); Work and school (Question 7); Personal relations (Questions 8 and 9); and Treatment (Question 10). The scoring of each question is as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "prevented work or studying"=3. The total score ranges from 0 to 30; higher scores indicate higher quality of life. Change from Week 52 was calculated as the post-Week 52 value minus the Week 52 value.
Time frame: Week 52; up to up to Week 104 of Extension Study (Week 52 was the first visit of this Treatment Extension study.)
Change From Week 52 in Children's Dermatology Life Quality Index (CDLQI) Total Score During the Extension Treatment Period
The CDLQI is the youth/children's version of the DLQI. The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Participants age \<16 years answered the questionnaire with: (1) very much; (2) a lot; (3) a little; or (4) not at all. The questionnaire was analyzed under 6 headings: Symptoms and feelings (Questions 1 and 2); Leisure (Questions 4, 5, and 6); School or holidays (Question 7); Personal relationships (Questions 3 and 8); Sleep (Question 9); and Treatment (Question 10). The scoring of each question is as follows: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. The total score ranges from 0 to 30; higher scores indicate higher quality of life. Change from Week 52 was calculated as the post-Week 52 value minus the Week 52 value.
Time frame: Week 52; up to Week 104 of Treatment Extension (Week 52 was the first visit of this Treatment Extension study.)
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
A TEAE was defined as any adverse event (AE) reported for the first time or the worsening of a pre-existing event after the first application of study drug in this study. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.
Time frame: up to approximately Week 108 (Week 52 was the first visit of this Treatment Extension study.)
Trough Plasma Concentrations of Ruxolitinib at Week 80 and Week 104
The steady-state plasma concentration was assessed. Pharmacokinetic blood samples could have been collected at any time prior to study drug application at the site at the Week 80 visit and at any time at the Week 104 (End of Trial) visit. Results from the two parent studies indicated that steady state was reached at or before Week 4, and that, hence, the use of vehicle or ruxolitinib 1.5% in the first 52 weeks of treatment had no impact on the ruxolitinib plasma concentration at the Week 80 and Week 104 (End of Treatment) visits. Thus, the two Cohort B cohorts were combined into a single arm for data analysis in this study.
Time frame: Weeks 80 (predose); Week 104 (any time post-dose) (Week 52 was the first visit of this Treatment Extension study.)
This study was conducted at 87 study centers in North America and Europe.
| Milestone | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Started | 58 | 58 | 118 | 224 |
| Completed | 41 | 50 | 92 | 173 |
| Not completed | 17 | 8 | 26 | 51 |
| Withdrew: Lost to follow-up | 3 | 3 | 3 | 10 |
| Withdrew: Withdrawal by subject | 14 | 5 | 18 | 33 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Site closed due to noncompliance | 0 | 0 | 0 | 1 |
| Withdrew: Discontinued due to covid-19 pandemic | 0 | 0 | 1 | 0 |
| Withdrew: Missed safety follow-up visit | 0 | 0 | 1 | 0 |
| Withdrew: Personal reasons | 0 | 0 | 0 | 1 |
| Withdrew: Not compliant with protocol-specific visit window | 0 | 0 | 0 | 1 |
Relapse was defined as a loss of 75% improvement from Baseline in the Face Vitiligo Area Scoring Index score (F-VASI75) response, assessed as percentage improvement in the F-VASI score at Baseline (Day 1 of the parent study) to \<75%.
| days | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Time to Relapse (Defined as <F-VASI75) | NA (238.0 to NA) | NA (NA to NA) | — | — |
Loss of adequate response was defined as a loss of 90% improvement from Baseline in the F-VASI score (F-VASI90) response, assessed as percentage improvement in the F-VASI score at Baseline (Day 1 of the parent study) to \<90%.
| days | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Time to Loss of Adequate Response | 195.0 (113.0 to 372.0) | NA (NA to NA) | — | — |
An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | 98.2 (90.6 to 100.0) | 98.2 (90.6 to 100.0) | 45.8 (36.6 to 55.2) | 65.6 (58.9 to 71.9) |
| Week 56 | 98.2 (90.4 to 100.0) | 96.4 (87.5 to 99.6) | 50.0 (40.2 to 59.8) | 69.4 (62.8 to 75.5) |
| Week 60 | 97.9 (88.9 to 99.9) | 98.1 (89.7 to 100.0) | 54.2 (44.3 to 63.9) | 69.2 (62.5 to 75.4) |
| Week 64 | 97.7 (87.7 to 99.9) | 100.0 (92.1 to 100.0) | 58.3 (48.5 to 67.7) | 72.0 (65.3 to 78.0) |
| Week 68 | 95.1 (83.5 to 99.4) | 100.0 (92.1 to 100.0) | 63.6 (53.7 to 72.6) | 77.1 (70.9 to 82.6) |
| Week 80 | 96.7 (82.8 to 99.9) | 100.0 (92.1 to 100.0) | 65.7 (55.4 to 74.9) | 78.9 (72.4 to 84.4) |
| Week 92 | 100.0 (85.2 to 100.0) | 97.7 (87.7 to 99.9) | 66.0 (55.5 to 75.4) | 84.4 (78.2 to 89.3) |
| Week 104 | 95.7 (78.1 to 99.9) | 100.0 (90.7 to 100.0) | 69.9 (59.5 to 79.0) | 86.4 (80.5 to 91.1) |
An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | 98.2 (90.6 to 100.0) | 98.2 (90.6 to 100.0) | 16.1 (10.0 to 24.0) | 30.8 (24.8 to 37.3) |
| Week 56 | 96.4 (87.7 to 99.6) | 96.4 (87.5 to 99.6) | 23.1 (15.6 to 32.2) | 34.7 (28.4 to 41.5) |
| Week 60 | 95.8 (85.7 to 99.5) | 90.4 (79.0 to 96.8) | 29.0 (20.6 to 38.5) | 40.8 (34.1 to 47.7) |
| Week 64 | 95.3 (84.2 to 99.4) | 97.8 (88.2 to 99.9) | 30.6 (22.1 to 40.2) | 43.5 (36.6 to 50.5) |
| Week 68 | 87.8 (73.8 to 95.9) | 100.0 (92.1 to 100.0) | 34.6 (25.6 to 44.4) | 48.6 (41.6 to 55.5) |
| Week 80 | 90.0 (73.5 to 97.9) | 100.0 (92.1 to 100.0) | 43.4 (33.5 to 53.8) | 54.6 (47.4 to 61.8) |
| Week 92 | 100.0 (85.2 to 100.0) | 97.7 (87.7 to 99.9) | 47.9 (37.5 to 58.4) | 60.3 (52.8 to 67.6) |
| Week 104 | 95.7 (78.1 to 99.9) | 97.4 (86.2 to 99.9) | 47.3 (36.9 to 57.9) | 66.1 (58.6 to 73.0) |
An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| percentage of participants | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | 98.2 (90.6 to 100.0) | 96.5 (87.9 to 99.6) | 0.0 (0.0 to 3.1) | 2.3 (0.7 to 5.2) |
| Week 56 | 89.3 (78.1 to 96.0) | 94.5 (84.9 to 98.9) | 3.7 (1.0 to 9.2) | 8.3 (5.0 to 12.9) |
| Week 60 | 83.3 (69.8 to 92.5) | 86.5 (74.2 to 94.4) | 8.4 (3.9 to 15.4) | 15.2 (10.6 to 20.7) |
| Week 64 | 72.1 (56.3 to 84.7) | 93.3 (81.7 to 98.6) | 11.1 (5.9 to 18.6) | 15.5 (10.8 to 21.1) |
| Week 68 | 68.3 (51.9 to 81.9) | 95.6 (84.9 to 99.5) | 12.1 (6.6 to 19.9) | 22.4 (16.9 to 28.6) |
| Week 80 | 80.0 (61.4 to 92.3) | 97.8 (88.2 to 99.9) | 22.2 (14.5 to 31.7) | 30.4 (24.0 to 37.4) |
| Week 92 | 78.3 (56.3 to 92.5) | 93.0 (80.9 to 98.5) | 24.5 (16.2 to 34.4) | 32.4 (25.6 to 39.8) |
| Week 104 | 69.6 (47.1 to 86.8) | 92.1 (78.6 to 98.3) | 28.0 (19.1 to 38.2) | 33.9 (27.0 to 41.4) |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).
| scores on a scale | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Baseline | 0.86 ± 0.492 | 0.99 ± 0.644 | 0.88 ± 0.543 | 0.91 ± 0.550 |
| Week 52 | 0.05 ± 0.110 | 0.07 ± 0.181 | 0.51 ± 0.459 | 0.39 ± 0.374 |
| Week 56 | 0.05 ± 0.108 | 0.07 ± 0.186 | 0.50 ± 0.475 | 0.38 ± 0.372 |
| Week 60 | 0.06 ± 0.145 | 0.09 ± 0.186 | 0.45 ± 0.450 | 0.35 ± 0.375 |
| Week 64 | 0.08 ± 0.131 | 0.08 ± 0.230 | 0.43 ± 0.456 | 0.33 ± 0.350 |
| Week 68 | 0.11 ± 0.199 | 0.04 ± 0.081 | 0.40 ± 0.430 | 0.31 ± 0.352 |
| Week 80 | 0.05 ± 0.082 | 0.04 ± 0.108 | 0.36 ± 0.426 | 0.27 ± 0.345 |
| Week 92 | 0.04 ± 0.055 | 0.04 ± 0.076 | 0.38 ± 0.471 | 0.23 ± 0.281 |
| Week 104 | 0.06 ± 0.109 | 0.04 ± 0.083 | 0.37 ± 0.493 | 0.21 ± 0.280 |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| scores on a scale | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | -0.81 ± 0.464 | -0.92 ± 0.591 | -0.37 ± 0.346 | -0.51 ± 0.448 |
| Week 56 | -0.82 ± 0.492 | -0.90 ± 0.594 | -0.39 ± 0.370 | -0.54 ± 0.457 |
| Week 60 | -0.84 ± 0.447 | -0.87 ± 0.570 | -0.43 ± 0.402 | -0.55 ± 0.457 |
| Week 64 | -0.80 ± 0.442 | -0.87 ± 0.527 | -0.44 ± 0.423 | -0.58 ± 0.452 |
| Week 68 | -0.73 ± 0.316 | -0.86 ± 0.518 | -0.46 ± 0.437 | -0.61 ± 0.476 |
| Week 80 | -0.75 ± 0.360 | -0.86 ± 0.508 | -0.49 ± 0.471 | -0.64 ± 0.478 |
| Week 92 | -0.76 ± 0.341 | -0.87 ± 0.548 | -0.48 ± 0.531 | -0.69 ± 0.488 |
| Week 104 | -0.72 ± 0.380 | -0.92 ± 0.561 | -0.50 ± 0.557 | -0.68 ± 0.514 |
F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percentage change | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | -94.45 ± 14.069 | -94.50 ± 8.990 | -44.32 ± 27.775 | -54.72 ± 31.006 |
| Week 56 | -93.79 ± 14.981 | -93.21 ± 12.573 | -46.19 ± 30.728 | -57.38 ± 31.256 |
| Week 60 | -93.85 ± 9.087 | -92.04 ± 13.198 | -50.55 ± 30.537 | -60.17 ± 30.147 |
| Week 64 | -89.64 ± 23.562 | -94.87 ± 8.079 | -52.32 ± 32.826 | -62.94 ± 27.427 |
| Week 68 | -87.98 ± 19.644 | -96.25 ± 4.633 | -55.27 ± 32.433 | -65.55 ± 30.388 |
| Week 80 | -93.24 ± 13.062 | -96.65 ± 4.683 | -58.60 ± 34.839 | -69.38 ± 29.091 |
| Week 92 | -95.77 ± 5.586 | -94.95 ± 10.366 | -55.44 ± 49.855 | -73.77 ± 25.490 |
| Week 104 | -90.53 ± 17.763 | -95.86 ± 7.213 | -56.53 ± 57.087 | -73.84 ± 31.780 |
A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percentage of participants | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | 80.7 (68.1 to 90.0) | 71.9 (58.5 to 83.0) | 16.9 (10.7 to 25.0) | 42.5 (35.9 to 49.3) |
| Week 56 | 76.8 (63.6 to 87.0) | 72.7 (59.0 to 83.9) | 16.7 (10.2 to 25.1) | 45.8 (39.1 to 52.7) |
| Week 60 | 83.3 (69.8 to 92.5) | 75.0 (61.1 to 86.0) | 19.6 (12.6 to 28.4) | 49.8 (42.8 to 56.7) |
| Week 64 | 74.4 (58.8 to 86.5) | 82.2 (67.9 to 92.0) | 21.3 (14.0 to 30.2) | 50.7 (43.7 to 57.7) |
| Week 68 | 70.7 (54.5 to 83.9) | 84.4 (70.5 to 93.5) | 29.9 (21.4 to 39.5) | 54.3 (47.3 to 61.2) |
| Week 80 | 80.0 (61.4 to 92.3) | 86.7 (73.2 to 94.9) | 39.4 (29.7 to 49.7) | 57.7 (50.4 to 64.8) |
| Week 92 | 73.9 (51.6 to 89.8) | 86.0 (72.1 to 94.7) | 48.9 (38.5 to 59.5) | 61.5 (53.9 to 68.6) |
| Week 104 | 60.9 (38.5 to 80.3) | 89.5 (75.2 to 97.1) | 54.8 (44.2 to 65.2) | 63.8 (56.3 to 70.9) |
A T-VASI75 responder achieved at least 75% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percentage of participants | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | 38.6 (26.0 to 52.4) | 42.1 (29.1 to 55.9) | 3.4 (0.9 to 8.5) | 12.2 (8.2 to 17.3) |
| Week 56 | 42.9 (29.7 to 56.8) | 43.6 (30.3 to 57.7) | 4.6 (1.5 to 10.5) | 13.4 (9.2 to 18.7) |
| Week 60 | 45.8 (31.4 to 60.8) | 38.5 (25.3 to 53.0) | 4.7 (1.5 to 10.6) | 14.2 (9.8 to 19.7) |
| Week 64 | 39.5 (25.0 to 55.6) | 48.9 (33.7 to 64.2) | 3.7 (1.0 to 9.2) | 16.9 (12.1 to 22.7) |
| Week 68 | 39.0 (24.2 to 55.5) | 42.2 (27.7 to 57.8) | 6.5 (2.7 to 13.0) | 22.4 (16.9 to 28.6) |
| Week 80 | 53.3 (34.3 to 71.7) | 48.9 (33.7 to 64.2) | 10.1 (5.0 to 17.8) | 23.7 (17.9 to 30.3) |
| Week 92 | 43.5 (23.2 to 65.5) | 53.5 (37.7 to 68.8) | 12.8 (6.8 to 21.2) | 29.1 (22.5 to 36.3) |
| Week 104 | 39.1 (19.7 to 61.5) | 55.3 (38.3 to 71.4) | 18.3 (11.0 to 27.6) | 30.5 (23.8 to 37.9) |
A T-VASI90 responder achieved at least 90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
| percentage of participants | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | 12.3 (5.1 to 23.7) | 12.3 (5.1 to 23.7) | 0.0 (0.0 to 3.1) | 2.3 (0.7 to 5.2) |
| Week 56 | 12.5 (5.2 to 24.1) | 14.5 (6.5 to 26.7) | 0.0 (0.0 to 3.4) | 3.2 (1.3 to 6.6) |
| Week 60 | 16.7 (7.5 to 30.2) | 17.3 (8.2 to 30.3) | 0.0 (0.0 to 3.4) | 3.8 (1.7 to 7.3) |
| Week 64 | 20.9 (10.0 to 36.0) | 20.0 (9.6 to 34.6) | 0.0 (0.0 to 3.4) | 2.9 (1.1 to 6.2) |
| Week 68 | 22.0 (10.6 to 37.6) | 20.0 (9.6 to 34.6) | 0.9 (0.0 to 5.1) | 4.3 (2.0 to 8.0) |
| Week 80 | 20.0 (7.7 to 38.6) | 20.0 (9.6 to 34.6) | 1.0 (0.0 to 5.5) | 6.7 (3.6 to 11.2) |
| Week 92 | 21.7 (7.5 to 43.7) | 20.9 (10.0 to 36.0) | 2.1 (0.3 to 7.5) | 8.9 (5.2 to 14.1) |
| Week 104 | 21.7 (7.5 to 43.7) | 23.7 (11.4 to 40.2) | 3.2 (0.7 to 9.1) | 9.6 (5.7 to 14.9) |
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).
| scores on a scale | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Baseline | 6.06 ± 2.056 | 6.27 ± 2.030 | 6.69 ± 2.150 | 6.74 ± 2.006 |
| Week 52 | 2.38 ± 2.206 | 2.36 ± 1.805 | 5.25 ± 3.248 | 3.90 ± 2.132 |
| Week 56 | 2.39 ± 2.253 | 2.31 ± 1.843 | 5.06 ± 3.151 | 3.80 ± 2.213 |
| Week 60 | 2.21 ± 2.176 | 2.30 ± 1.841 | 4.86 ± 3.150 | 3.58 ± 2.122 |
| Week 64 | 2.33 ± 2.210 | 1.94 ± 1.717 | 4.85 ± 3.317 | 3.57 ± 2.051 |
| Week 68 | 2.45 ± 2.231 | 1.76 ± 1.378 | 4.51 ± 3.060 | 3.43 ± 2.160 |
| Week 80 | 2.05 ± 2.233 | 1.73 ± 1.331 | 4.18 ± 3.036 | 3.18 ± 2.017 |
| Week 92 | 2.17 ± 1.913 | 1.65 ± 1.244 | 4.12 ± 3.477 | 3.04 ± 2.128 |
| Week 104 | 2.86 ± 3.269 | 1.54 ± 1.227 | 4.00 ± 4.208 | 2.92 ± 2.061 |
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Change from Baseline=post-Baseline value minus the Baseline value.
| scores on a scale | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | -3.68 ± 1.564 | -3.91 ± 1.526 | -1.45 ± 2.271 | -2.83 ± 1.938 |
| Week 56 | -3.71 ± 1.615 | -3.91 ± 1.503 | -1.69 ± 2.217 | -2.97 ± 2.086 |
| Week 60 | -3.79 ± 1.692 | -3.95 ± 1.585 | -1.83 ± 2.161 | -3.16 ± 2.027 |
| Week 64 | -3.60 ± 2.033 | -4.20 ± 1.569 | -1.84 ± 2.375 | -3.21 ± 2.060 |
| Week 68 | -3.44 ± 1.789 | -4.24 ± 1.534 | -2.21 ± 2.273 | -3.35 ± 2.143 |
| Week 80 | -3.79 ± 1.663 | -4.26 ± 1.519 | -2.49 ± 2.175 | -3.55 ± 2.109 |
| Week 92 | -3.85 ± 1.545 | -4.33 ± 1.673 | -2.61 ± 2.624 | -3.73 ± 2.246 |
| Week 104 | -3.05 ± 2.156 | -4.48 ± 1.702 | -2.71 ± 3.479 | -3.84 ± 2.151 |
T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.
| percentage change | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | -65.01 ± 23.969 | -64.95 ± 21.547 | -24.75 ± 2.271 | -42.14 ± 25.783 |
| Week 56 | -65.16 ± 24.916 | -65.69 ± 22.042 | -28.05 ± 30.487 | -43.91 ± 27.408 |
| Week 60 | -66.83 ± 26.478 | -65.58 ± 22.910 | -31.01 ± 28.944 | -47.00 ± 26.089 |
| Week 64 | -62.82 ± 33.328 | -70.44 ± 20.212 | -30.85 ± 32.898 | -46.96 ± 26.395 |
| Week 68 | -61.40 ± 29.204 | -71.89 ± 17.942 | -35.53 ± 32.135 | -49.41 ± 27.629 |
| Week 80 | -68.99 ± 26.870 | -72.21 ± 17.852 | -40.97 ± 30.033 | -52.48 ± 26.991 |
| Week 92 | -66.95 ± 24.885 | -72.55 ± 19.152 | -43.34 ± 34.425 | -55.00 ± 28.995 |
| Week 104 | -58.38 ± 35.533 | -74.66 ± 17.727 | -45.52 ± 41.968 | -56.96 ± 27.409 |
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Data are presented as the percentage of BSA involvement in the face as compared to total BSA.
| percentage BSA | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Baseline | 0.92 ± 0.498 | 1.10 ± 0.745 | 1.01 ± 0.632 | 1.02 ± 0.636 |
| Week 52 | 0.18 ± 0.240 | 0.27 ± 0.401 | 0.81 ± 0.641 | 0.70 ± 0.568 |
| Week 56 | 0.18 ± 0.198 | 0.27 ± 0.416 | 0.77 ± 0.638 | 0.67 ± 0.572 |
| Week 60 | 0.20 ± 0.225 | 0.25 ± 0.309 | 0.73 ± 0.616 | 0.63 ± 0.557 |
| Week 64 | 0.20 ± 0.206 | 0.20 ± 0.271 | 0.71 ± 0.607 | 0.61 ± 0.566 |
| Week 68 | 0.22 ± 0.258 | 0.16 ± 0.183 | 0.67 ± 0.581 | 0.57 ± 0.548 |
| Week 80 | 0.12 ± 0.138 | 0.15 ± 0.200 | 0.62 ± 0.565 | 0.55 ± 0.564 |
| Week 92 | 0.10 ± 0.130 | 0.15 ± 0.180 | 0.64 ± 0.595 | 0.49 ± 0.527 |
| Week 104 | 0.13 ± 0.154 | 0.15 ± 0.181 | 0.62 ± 0.602 | 0.47 ± 0.509 |
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented as the percentage of BSA involvement in the face as compared to total BSA.
| percentage BSA | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | -0.74 ± 0.402 | -0.83 ± 0.638 | -0.20 ± 0.313 | -0.31 ± 0.435 |
| Week 56 | -0.76 ± 0.458 | -0.82 ± 0.672 | -0.25 ± 0.345 | -0.35 ± 0.433 |
| Week 60 | -0.77 ± 0.441 | -0.80 ± 0.601 | -0.28 ± 0.364 | -0.38 ± 0.454 |
| Week 64 | -0.74 ± 0.446 | -0.83 ± 0.625 | -0.29 ± 0.417 | -0.41 ± 0.457 |
| Week 68 | -0.69 ± 0.345 | -0.86 ± 0.657 | -0.31 ± 0.425 | -0.45 ± 0.489 |
| Week 80 | -0.74 ± 0.381 | -0.87 ± 0.637 | -0.37 ± 0.494 | -0.48 ± 0.521 |
| Week 92 | -0.76 ± 0.374 | -0.87 ± 0.678 | -0.36 ± 0.558 | -0.54 ± 0.532 |
| Week 104 | -0.70 ± 0.400 | -0.93 ± 0.716 | -0.39 ± 0.604 | -0.54 ± 0.548 |
F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
| percentage change | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | -80.75 ± 18.726 | -76.75 ± 23.470 | -22.15 ± 28.268 | -29.06 ± 36.354 |
| Week 56 | -80.23 ± 21.828 | -74.42 ± 35.048 | -26.20 ± 30.604 | -33.66 ± 33.944 |
| Week 60 | -79.20 ± 19.463 | -77.67 ± 20.946 | -30.04 ± 30.751 | -36.86 ± 33.289 |
| Week 64 | -75.92 ± 32.175 | -80.06 ± 22.142 | -30.67 ± 33.473 | -39.58 ± 31.992 |
| Week 68 | -77.11 ± 23.565 | -83.14 ± 21.999 | -32.60 ± 34.575 | -43.61 ± 32.549 |
| Week 80 | -84.55 ± 18.730 | -84.67 ± 22.014 | -36.79 ± 36.826 | -46.38 ± 34.407 |
| Week 92 | -87.81 ± 15.738 | -83.24 ± 23.746 | -34.05 ± 50.762 | -51.96 ± 31.510 |
| Week 104 | -82.87 ± 23.245 | -84.09 ± 22.920 | -35.82 ± 52.646 | -52.85 ± 32.983 |
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Data are presented as the percentage of BSA involvement in the total body.
| percentage BSA | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Baseline | 6.79 ± 2.157 | 6.85 ± 1.924 | 7.42 ± 2.064 | 7.49 ± 2.006 |
| Week 52 | 4.09 ± 2.838 | 4.20 ± 2.640 | 6.95 ± 3.403 | 5.96 ± 2.352 |
| Week 56 | 4.11 ± 2.880 | 4.13 ± 2.788 | 6.73 ± 3.281 | 5.81 ± 2.558 |
| Week 60 | 3.77 ± 2.756 | 4.09 ± 2.833 | 6.61 ± 3.262 | 5.64 ± 2.479 |
| Week 64 | 3.98 ± 3.087 | 3.49 ± 2.452 | 6.67 ± 3.448 | 5.64 ± 2.483 |
| Week 68 | 3.92 ± 2.813 | 3.27 ± 2.310 | 6.46 ± 3.239 | 5.51 ± 2.682 |
| Week 80 | 3.72 ± 3.151 | 3.18 ± 2.232 | 6.09 ± 3.313 | 5.27 ± 2.581 |
| Week 92 | 3.94 ± 2.834 | 3.04 ± 2.194 | 5.96 ± 3.646 | 5.15 ± 2.741 |
| Week 104 | 4.56 ± 4.156 | 2.93 ± 2.301 | 5.91 ± 4.475 | 5.07 ± 2.699 |
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Data are presented as the percentage of BSA involvement in the total body.
| percentage BSA | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | -2.70 ± 1.830 | -2.64 ± 1.906 | -0.47 ± 2.325 | -1.52 ± 1.711 |
| Week 56 | -2.74 ± 1.918 | -2.70 ± 1.983 | -0.73 ± 2.238 | -1.71 ± 2.059 |
| Week 60 | -2.95 ± 1.910 | -2.75 ± 2.195 | -0.80 ± 2.128 | -1.86 ± 1.978 |
| Week 64 | -2.73 ± 2.528 | -3.22 ± 1.883 | -0.73 ± 2.432 | -1.90 ± 2.052 |
| Week 68 | -2.73 ± 1.958 | -3.34 ± 1.922 | -0.98 ± 2.262 | -2.03 ± 2.180 |
| Week 80 | -3.05 ± 2.083 | -3.42 ± 1.809 | -1.31 ± 2.341 | -2.21 ± 2.169 |
| Week 92 | -3.03 ± 1.664 | -3.58 ± 1.938 | -1.49 ± 2.753 | -2.36 ± 2.380 |
| Week 104 | -2.18 ± 2.723 | -3.72 ± 2.075 | -1.52 ± 3.672 | -2.42 ± 2.307 |
T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.
| percentage change | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | -43.81 ± 27.916 | -41.50 ± 28.747 | -8.54 ± 28.806 | -20.57 ± 23.042 |
| Week 56 | -44.22 ± 29.590 | -43.12 ± 29.489 | -11.96 ± 28.156 | -22.98 ± 26.032 |
| Week 60 | -47.61 ± 29.237 | -43.09 ± 31.608 | -13.40 ± 26.410 | -25.12 ± 25.564 |
| Week 64 | -43.29 ± 40.045 | -50.59 ± 27.166 | -12.00 ± 30.202 | -25.15 ± 26.860 |
| Week 68 | -44.53 ± 30.086 | -52.51 ± 26.921 | -15.01 ± 29.093 | -27.59 ± 28.476 |
| Week 80 | -50.51 ± 33.794 | -53.98 ± 25.682 | -20.22 ± 30.154 | -29.92 ± 27.996 |
| Week 92 | -48.53 ± 29.457 | -55.56 ± 26.401 | -22.84 ± 33.708 | -31.98 ± 30.805 |
| Week 104 | -40.84 ± 40.076 | -57.40 ± 27.898 | -24.26 ± 42.193 | -32.96 ± 29.907 |
The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.
| percentage of participants | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | 49.1 (35.6 to 62.7) | 42.1 (29.1 to 55.9) | 11.9 (6.6 to 19.1) | 35.3 (29.0 to 42.0) |
| Week 56 | 48.2 (34.7 to 62.0) | 34.5 (22.2 to 48.6) | 20.4 (13.2 to 29.2) | 30.1 (24.1 to 36.7) |
| Week 60 | 46.9 (32.5 to 61.7) | 28.8 (17.1 to 43.1) | 19.6 (12.6 to 28.4) | 27.6 (21.7 to 34.2) |
| Week 64 | 53.5 (37.7 to 68.8) | 37.8 (23.8 to 53.5) | 23.1 (15.6 to 32.2) | 28.2 (22.1 to 34.8) |
| Week 68 | 46.3 (30.7 to 62.6) | 46.7 (31.7 to 62.1) | 20.6 (13.4 to 29.5) | 33.8 (27.4 to 40.6) |
| Week 80 | 38.7 (21.8 to 57.8) | 42.2 (27.7 to 57.8) | 28.3 (19.7 to 38.2) | 32.8 (26.3 to 39.9) |
| Week 92 | 39.1 (19.7 to 61.5) | 37.2 (23.0 to 53.3) | 28.4 (19.6 to 38.6) | 41.1 (33.8 to 48.7) |
| Week 104 | 56.5 (34.5 to 76.8) | 50.0 (33.4 to 66.6) | 30.1 (21.0 to 40.5) | 43.3 (35.9 to 50.9) |
The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Participants age ≥16 years answered the questionnaire with: (1) very much; (2) a lot; (3) a little; or (4) not at all. The questionnaire was analyzed under 6 headings: Symptoms and feelings (Questions 1 and 2); Daily activities (Questions 3 and 4); Leisure (Questions 5 and 6); Work and school (Question 7); Personal relations (Questions 8 and 9); and Treatment (Question 10). The scoring of each question is as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "prevented work or studying"=3. The total score ranges from 0 to 30; higher scores indicate higher quality of life. Change from Week 52 was calculated as the post-Week 52 value minus the Week 52 value.
| scores on a scale | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | 2.87 ± 3.059 | 4.10 ± 4.784 | 3.69 ± 3.428 | 3.53 ± 4.150 |
| Change from Week 52 at Week 56 | 0.11 ± 2.054 | -0.47 ± 1.757 | -0.05 ± 2.138 | -0.22 ± 2.483 |
| Change from Week 52 at Week 60 | 0.37 ± 2.388 | 0.13 ± 2.227 | 0.28 ± 2.491 | 0.24 ± 2.929 |
| Change from Week 52 at Week 64 | 0.35 ± 2.578 | 0.18 ± 2.630 | -0.06 ± 2.712 | -0.14 ± 2.350 |
| Change from Week 52 at Week 68 | -0.08 ± 2.508 | -0.15 ± 2.202 | -0.17 ± 2.501 | 0.08 ± 2.454 |
| Change from Week 52 at Week 80 | 0.03 ± 3.006 | -0.23 ± 2.315 | -0.77 ± 2.871 | -0.13 ± 2.809 |
| Change from Week 52 at Week 92 | 0.27 ± 2.354 | -0.23 ± 1.898 | -0.89 ± 2.383 | -0.22 ± 2.941 |
| Change from Week 52 at Week 104 | 0.57 ± 2.135 | -0.40 ± 1.538 | -0.48 ± 2.277 | -0.06 ± 2.813 |
The CDLQI is the youth/children's version of the DLQI. The DLQI is a simple, 10-question validated questionnaire to measure how much the skin problem has affected the participant over the previous 7 days. Participants age \<16 years answered the questionnaire with: (1) very much; (2) a lot; (3) a little; or (4) not at all. The questionnaire was analyzed under 6 headings: Symptoms and feelings (Questions 1 and 2); Leisure (Questions 4, 5, and 6); School or holidays (Question 7); Personal relationships (Questions 3 and 8); Sleep (Question 9); and Treatment (Question 10). The scoring of each question is as follows: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. The total score ranges from 0 to 30; higher scores indicate higher quality of life. Change from Week 52 was calculated as the post-Week 52 value minus the Week 52 value.
| scores on a scale | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|
| Week 52 | 1.67 ± 2.887 | 1.00 ± 0.632 | 1.25 ± 1.893 | 2.32 ± 3.872 |
| Change from Week 52 at Week 56 | -1.00 ± 2.646 | -0.17 ± 0.753 | 0.00 ± 0.816 | 0.36 ± 1.989 |
| Change from Week 52 at Week 60 | 0.00 ± 0.000 | -0.50 ± 0.548 | -0.50 ± 0.577 | -0.41 ± 2.108 |
| Change from Week 52 at Week 64 | -1.33 ± 2.309 | 0.00 ± 0.707 | -1.00 ± 1.414 | -0.36 ± 1.399 |
| Change from Week 52 at Week 68 | -0.67 ± 1.155 | 0.40 ± 1.140 | 0.50 ± 0.577 | -0.23 ± 1.541 |
| Change from Week 52 at Week 80 | -2.00 ± 2.828 | -0.40 ± 0.548 | -0.75 ± 1.708 | 0.15 ± 1.814 |
| Change from Week 52 at Week 92 | NA ± NA | 0.25 ± 1.258 | -0.25 ± 0.957 | 0.70 ± 3.614 |
| Change from Week 52 at Week 104 | -0.50 ± 0.707 | -0.67 ± 1.155 | -1.25 ± 1.893 | -0.20 ± 4.086 |
A TEAE was defined as any adverse event (AE) reported for the first time or the worsening of a pre-existing event after the first application of study drug in this study. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment.
| Participants | Cohort A: Vehicle Cream BID | Cohort A: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID |
|---|---|---|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 21 | 3 | 32 | 59 | 114 |
The steady-state plasma concentration was assessed. Pharmacokinetic blood samples could have been collected at any time prior to study drug application at the site at the Week 80 visit and at any time at the Week 104 (End of Trial) visit. Results from the two parent studies indicated that steady state was reached at or before Week 4, and that, hence, the use of vehicle or ruxolitinib 1.5% in the first 52 weeks of treatment had no impact on the ruxolitinib plasma concentration at the Week 80 and Week 104 (End of Treatment) visits. Thus, the two Cohort B cohorts were combined into a single arm for data analysis in this study.
| nanomolar | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID | Cohorts A and B: Ruxolitinib 1.5% Cream BID |
|---|---|---|---|
| 12 to <18 years | 7.28 ± 11.7 | 5.56 ± 10.5 | 5.85 ± 10.6 |
| 18 to <65 years | 15.1 ± 19.5 | 12.7 ± 17.2 | 13.1 ± 17.6 |
| ≥65 years | 13.0 ± 9.44 | 25.7 ± 20.9 | 24.3 ± 20.2 |
| Overall | 13.8 ± 18.1 | 12.8 ± 17.4 | 12.9 ± 17.5 |
Collected over up to approximately Week 108 (Week 52 was the first visit of this Treatment Extension study.). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle Cream BID | 0/58 (0%) | 0/58 (0%) | 6/58 (10.3%) |
| Ruxolitinib 1.5% Cream BID | 0/423 (0%) | 12/423 (2.8%) | 55/423 (13%) |
| Total | 0/458 (0%) | 12/458 (2.6%) | 61/458 (13.3%) |
| Event | Vehicle Cream BID | Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/58 | 1/423 | 1/458 |
| Angina pectorisCardiac disorders | 0/58 | 1/423 | 1/458 |
| Bipolar I disorderPsychiatric disorders | 0/58 | 1/423 | 1/458 |
| COVID-19 pneumoniaInfections and infestations | 0/58 | 1/423 | 1/458 |
| CholelithiasisHepatobiliary disorders | 0/58 | 1/423 | 1/458 |
| CystoceleReproductive system and breast disorders | 0/58 | 1/423 | 1/458 |
| Hip fractureInjury, poisoning and procedural complications | 0/58 | 1/423 | 1/458 |
| Intervertebral disc disorderMusculoskeletal and connective tissue disorders | 0/58 | 1/423 | 1/458 |
| Mental status changesPsychiatric disorders | 0/58 | 1/423 | 1/458 |
| OtosclerosisEar and labyrinth disorders | 0/58 | 1/423 | 1/458 |
| Event | Vehicle Cream BID | Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|
| COVID-19Infections and infestations | 6/58 | 55/423 | 61/458 |
| Age, Continuous(years) | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|---|---|
| Mean | 39.3 ± 12.49 | 42.9 ± 15.95 | 39.7 ± 14.62 | 39.3 ± 16.45 | 39.9 ± 15.47 |
| Sex: Female, Male(Participants) | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|---|---|
| Female | 31 | 33 | 61 | 129 | 254 |
| Male | 27 | 25 | 57 | 95 | 204 |
| Race/Ethnicity, Customized(Participants) | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|---|---|
| Asian | 4 | 3 | 3 | 8 | 18 |
| Black or African American | 5 | 4 | 3 | 11 | 23 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 | 2 |
| Not Reported | 2 | 1 | 3 | 13 | 19 |
| White | 42 | 48 | 107 | 180 | 377 |
| Captured as Latino in Database | 1 | 0 | 0 | 0 | 1 |
| Persian | 1 | 0 | 0 | 0 | 1 |
| Indo-Caribbean | 1 | 0 | 0 | 0 | 1 |
| Jordanian | 1 | 0 | 0 | 0 | 1 |
| Brazilian | 0 | 1 | 0 | 0 | 1 |
| Guyana | 0 | 1 | 0 | 0 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Cape Verdean | 0 | 0 | 1 | 1 | 2 |
| Dominican Republic | 0 | 0 | 1 | 0 | 1 |
| Captured as Hispanic or Latino in Database | 0 | 0 | 0 | 1 | 1 |
| Iranian | 0 | 0 | 0 | 1 | 1 |
| Indian | 0 | 0 | 0 | 1 | 1 |
| North African | 0 | 0 | 0 | 1 | 1 |
| Middle Eastern | 0 | 0 | 0 | 1 | 1 |
| Arab//North-African | 0 | 0 | 0 | 1 | 1 |
| White/Black/Asian | 0 | 0 | 0 | 1 | 1 |
| Mexican | 0 | 0 | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Cohort A: Vehicle Cream BID | Cohort A: Ruxolitinib 1.5% Cream BID | Cohort B: Vehicle Cream BID to Ruxolitinib 1.5% Cream BID | Cohort B: Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 13 | 16 | 53 | 93 |
| Not Hispanic or Latino | 45 | 43 | 99 | 157 | 344 |
| Not Reported | 2 | 1 | 3 | 11 | 17 |
| Unknown | 0 | 0 | 0 | 1 | 1 |
| Captured as Other in Database | 0 | 1 | 0 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Sep 2020 to primary completion in Nov 2022, 25 months.
Results were first posted in Jul 2023, 8 months after primary completion.
Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib